Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 1, 2021

Rhea-AI Summary

Cellectis S.A. held its Annual Shareholders’ General Meeting on June 1, 2021, in Paris, with over 66% of voting rights exercised. Resolutions 1-24 passed, while Resolution 25 was rejected. The detailed voting results can be found on the company's website. Cellectis is pioneering allogeneic CAR-T therapies, focusing on off-the-shelf gene-edited CAR T-cells aimed at treating cancers like acute myeloid leukemia and multiple myeloma. The company is based in Paris, with additional offices in New York and Raleigh, and trades on Nasdaq under the symbol CLLS.

Positive

• Adoption of 24 out of 25 resolutions indicates shareholder support.
• Pioneering allogeneic CAR-T immunotherapy positions Cellectis in a growing market.

Negative

• Resolution 25 rejection may reflect shareholder concerns.

NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 1, 2021 at its head office in Paris, France.

At the meeting, during which more than 66% of voting rights were exercised, Resolutions 1 through 24 were adopted. Resolution 25 was rejected.

The detailed results of the vote and the resolutions are available on the company’s website:
https://www.cellectis.com/en/investors/general-meetings/

About Cellectis

Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to targetand eradicate cancer cells.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).

Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visitwww.cellectis.com

Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.
TALEN® is a registered trademark owned by Cellectis

For further information, please contact:

Media contacts:
Margaret Gandolfo, Senior Manager, Communications 646-628-0300, Margaret.gandolfo@cellectis.com

Conor McGoldrick, Zeno Group, 914-355-0927, Conor.Mcgoldrick@zenogroup.com

IR contact:
Simon Harnest, Chief Investment Officer, 646-385-9008, simon.harnest@cellectis.com

Attachment

• 20210601_PR_post AG_ANG_MBT

FAQ

What were the outcomes of Cellectis' Annual Shareholders’ General Meeting on June 1, 2021?

During the meeting, 24 resolutions were adopted, while one resolution was rejected.

What is the current stock symbol for Cellectis?

Cellectis trades on Nasdaq under the stock symbol CLLS.

What is Cellectis developing in the field of oncology?

Cellectis is developing allogeneic CAR-T immunotherapies, focusing on off-the-shelf gene-edited CAR T-cells.

How many voting rights were exercised at Cellectis' Annual Meeting?

More than 66% of voting rights were exercised at the meeting.

Where is Cellectis headquartered?

Cellectis is headquartered in Paris, France.